The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Brentuximab vedotin versus pembrolizumab in R/R classical Hodgkin lymphoma
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares some insights into factors to consider when selecting between brentuximab vedotin and pembrolizumab when treating patients with Hodgkin lymphoma (HL), citing the results of the KEYNOTE-204 trial (NCT02684292), which compared the two. Although this trial showed that pembrolizumab treatment resulted in a longer duration of remission and progression-free survival (PFS), Dr Collins explains that the sequencing of these agents will vary on a case-by-case basis, and comments on the importance of considering patient-specific factors when making treatment decisions. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Received honoraria for speaker and advisory work from:
Takeda, Gilead, Roche, Novartis, Incyte, Daiichi Sankyo, Beigene, ADC Therapeutics, Celleron, SecuraBio
Received research funding from:
BMS, MSD, Pfizer, Amgen, Celgene, Beigene
